General drug use-results survey of Hiyasta tablets (ATL)
Not Applicable
Recruiting
- Conditions
- Relapsed or refractory adult T-cell leukemia/lymphoma (ATL)
- Registration Number
- JPRN-jRCT2031210409
- Lead Sponsor
- Post Marketing Surveillance Post Marketing Surveillance Dept.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
All patients with relapsed or refractory ATL to whom Hiyasta tablets is administered.
Patients with histopathologically or cytologically diagnosed relapsed or refractory adult T-cell leukemia-lymphoma confirmed as seropositive for anti-Human T-lymphotrophic Virus type-I (HTLV-1) antibody.
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the occurrence of myelosuppression, interstitial lung disease, infectious disease, and arrhythmia (including QT interval prolongation) under actual use conditions in patients with relapsed or refractory ATL treated with tucidinostat.
- Secondary Outcome Measures
Name Time Method